Compare Micron Technology, Inc. (MU) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs Tango Therapeutics Inc. — how do they compare? Micron Technology, Inc. trades at $875.44 (market cap $1.08T), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Micron Technology, Inc. is far larger — about 288× Tango Therapeutics Inc.'s market cap, and Micron Technology, Inc. pays a 0.06% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Micron Technology, Inc. for 49 Days and Tango Therapeutics Inc. for 0 Days on average.
| MU | TNGX | |
|---|---|---|
Market Cap | $1.08T | $3.75B |
Volume | 28,906,235 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $1.21K | $32.90 |
52-Week Low | $191.94 | $7.50 |
Typical Hold Time | 49 Days | 0 Days |
Enterprise Value | $1.04T | $2.77B |
Dividend Yield | 0.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) is trading at $914.13, down 7.57% today, following strong recent performance. The stock shows robust fundamentals with a P/E of 12.82, net income margin of 63.8%, and consistent earnings beats. Technical indicators show a bullish moving average signal despite today's pullback, with support at $978. The company benefits from strong AI-driven memory demand and strategic customer agreements covering 35% of revenue through 2030.
Outlook remains positive with analyst consensus at 82.85% buy ratings and $1,590 price target. Key opportunities include sustained AI memory demand and reduced cyclicality through long-term contracts. Risks include potential growth deceleration in 2028 and market volatility. The stock's current valuation appears reasonable given strong profitability and growth trajectory.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
